Applied DNA Sciences announced that its Applied DNA Clinical Labs molecular diagnostics subsidiary will use GenXys Health Care Systems' clinical decision support software for interpretation and reporting in its TR8 pharmacogenomic (TR8 PGx) test.
The intent of the partnership is to improve patient outcomes and reduce healthcare costs through a data-driven approach that relates an individual's genetic factors to potential responses to prescription drugs, the companies said in a statement.
Applied DNA's TR8 PGx assay simultaneously investigates 120 genetic variants across more than 30 genes that may affect the efficacy and safety of medications by affecting the rates at which the body absorbs, activates, distributes, and metabolizes the drugs. The genetic variations targeted by TR8 PGx have been shown to be relevant to a broad range of drugs, including those for cardiac, pain management, cancer, and psychiatric indications, according to the companies.
The genetic variants identified by the TR8 PGx test will be processed by the GenXys software to identify potentially actionable drug-gene interactions; this information will help guide healthcare providers in making prescribing decisions and treatment plans.
The test will be run in Applied DNA Clinical Labs' laboratory, which is Clinical Laboratory Evaluation Program permitted and Clinical Laboratory Improvement Amendments certified. The TR8 PGx test and testing service was approved recently by the New York State Department of Health for commercial use.
